Last reviewed · How we verify
FGF-1
At a glance
| Generic name | FGF-1 |
|---|---|
| Also known as | Acidic FGF |
| Sponsor | CardioVascular BioTherapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of IL-8, FGF-1 and VEGF Levels in Pulpal Tissue, GCF and Dentinal Fluid Samples of Healthy, Reversible and Irreversible Pulpitis Diagnosed Teeth
- Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects (PHASE1, PHASE2)
- The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome (NA)
- Low Flow Anesthesia in Children Undergoing Strabismus Surgery (PHASE4)
- A Safety and Efficacy Trial of TTHX1114 in People With CED (PHASE2)
- A Phase 1/ Phase 2 Study of TTHX1114(NM141) (PHASE1, PHASE2)
- Intranasal Human FGF-1 for Subjects With Parkinson's Disease (PHASE1)
- Comparison of the Effects of High, Low and Minimal Flow Anesthesia Managements on ORI and Partial Oxygen Pressure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FGF-1 CI brief — competitive landscape report
- FGF-1 updates RSS · CI watch RSS
- CardioVascular BioTherapeutics, Inc. portfolio CI